Selected article for: "acute kidney injury and lung tissue"
Author: Al-kuraishy, Hayder M.; Al-Gareeb, Ali I.
Title: Acute kidney injury and COVID-19
  • Cord-id: uce02h0t
  • Document date: 2021_10_6
    • ID: uce02h0t
    Snippet: BACKGROUND: Coronavirus disease 2019 (COVID-19) is a recent pandemic infectious disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2). COVID-19 may lead to acute kidney injury (AKI). MAIN TEXT: SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) and dipeptidyl peptidase 4(DPP4) as entry point receptors in the alveolar type II cell of the lung. However, the expression of ACE2 is 100-fold higher in kidney tissue than the lung, though the potential entry point of SARS-CoV-
    Document: BACKGROUND: Coronavirus disease 2019 (COVID-19) is a recent pandemic infectious disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2). COVID-19 may lead to acute kidney injury (AKI). MAIN TEXT: SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) and dipeptidyl peptidase 4(DPP4) as entry point receptors in the alveolar type II cell of the lung. However, the expression of ACE2 is 100-fold higher in kidney tissue than the lung, though the potential entry point of SARS-CoV-2 for renal tissue and induction of AKI remains undefined. Therefore, reduction of ACE2 and high circulating angiotensin II in COVID-19 may together participate in the induction of AKI. Thereby, direct ACE2 activator is under investigation to be used as an effective therapy in the management COVID-19-induced AKI. Besides, the direct effect via invasion of SARS-CoV-2 may lead to glomerulopathy and renal proximal tubular necrosis. CONCLUSION: COVID-19 may associate with AKI due to direct effect of SARS-CoV-2 through ACE2 and DPP4 receptors or indirectly through the development of cytokine storm. Both ACE2 and DPP4 are interacted mutually in the pathogenesis of AKI. Thus, DPP4 inhibitors or ACE2 activators could reverse early AKI in COVID-19. Therefore, emerging of clinical trials is warranted to confirm the role of ACE2 and DPP4 modulators in COVID-19-induced AKI.

    Search related documents:
    Co phrase search for related documents
    • acute aki kidney injury and lmwh molecular weight heparin: 1, 2
    • acute aki kidney injury and longitudinal cohort: 1, 2, 3
    • acute aki kidney injury and longitudinal cohort study: 1, 2, 3
    • acute aki kidney injury and low lmwh molecular weight heparin: 1, 2
    • acute aki kidney injury and low molecular heparin: 1, 2, 3, 4, 5
    • acute aki kidney injury and lung damage: 1, 2
    • acute aki kidney injury and lung kidney: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute ards respiratory distress syndrome and liver function: 1, 2, 3, 4, 5, 6, 7, 8
    • acute ards respiratory distress syndrome and lmwh molecular weight heparin: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and low lmwh molecular weight heparin: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and low molecular heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute ards respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung kidney: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • acute kidney and longitudinal cohort: 1, 2, 3, 4, 5
    • acute kidney and longitudinal cohort study: 1, 2, 3, 4, 5
    • acute kidney and low lmwh molecular weight heparin: 1, 2, 3
    • acute kidney and low molecular heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute kidney and lung damage: 1, 2, 3, 4, 5, 6
    • acute kidney and lung kidney: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25